Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.
Researchers have developed and validated a score for predicting the risk for hepatocellular carcinoma in Asian patients with chronic hepatitis B virus infection who are taking oral antiviral therapy.
Two meta-analyses published in the Journal of Viral Hepatitis confirm that patients with hepatitis B virus infection remain at risk for hepatocellular carcinoma even after achieving positive virologic outcomes, and identify factors associated with the risk.
Results of a real-world study suggest that changing from a dry powder inhaler to a pressurized metered-dose inhaler is not associated with compromised treatment outcomes among patients with asthma.
Systemic corticosteroid treatment reduces blood eosinophil counts and low levels are maintained for weeks after treatment is discontinued, show real-world data.